Literature DB >> 8092978

Androgen insensitivity syndrome.

M N Patterson1, M J McPhaul, I A Hughes.   

Abstract

In a relatively short period of time, understanding of the fundamental causes of androgen insensitivity syndromes has improved dramatically. This has been brought about by the combination of several disciplines, including endocrinology, genetics, developmental and molecular biology. Mutations can be identified in the androgen receptor gene in suspected cases of AIS, and their functional consequences examined in various in-vitro systems. This information can then be correlated with the clinical presentation of the patient, and is beginning to provide an explanation for the highly variable clinical presentation of AIS. It is to be hoped that this information will also help to predict the likely outcome of androgen therapy in infants with PAIS and an intersex phenotype. More speculatively, functional studies may also lead to novel strategies for the treatment of patients. This would then be of enormous benefit to both patient and parents. Furthermore, the identification of a mutation allows precise information for genetic counselling of families affected by AIS. However, many questions still remain to challenge clinicians and scientists alike. These include the risk of testicular malignancy in patients with AIS and currently there is no worldwide consensus on the stage at which testes should be removed from patients reared as female. There are also significant challenges in patient counselling. Although there is greater understanding of the molecular defects that cause AIS, there are several examples of patients with a similar degree of receptor dysfunction, or even the same mutation, but whose phenotypes are widely different. Other factors must therefore contribute to the clinical presentation of AIS, although these have not been identified. Finally, there are the mutations in patients with Kennedy's disease. The consequences of the mutations are unexplained and are a clear indication that there is still a great deal to discover about the function and biology of androgen receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092978     DOI: 10.1016/s0950-351x(05)80258-7

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  7 in total

Review 1.  Mammary gland development and tumorigenesis in estrogen receptor knockout mice.

Authors:  W P Bocchinfuso; K S Korach
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

2.  Androgen insensitivity syndrome: a survey of diagnostic procedures and management in the UK.

Authors:  R M Viner; Y Teoh; D M Williams; M N Patterson; I A Hughes
Journal:  Arch Dis Child       Date:  1997-10       Impact factor: 3.791

3.  Down syndrome in association with features of the androgen insensitivity syndrome.

Authors:  R M Viner; N Shimura; B D Brown; A J Green; I A Hughes
Journal:  J Med Genet       Date:  1996-07       Impact factor: 6.318

4.  Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study.

Authors:  Cindy Ke Zhou; Paul H Levine; Sean D Cleary; Heather J Hoffman; Barry I Graubard; Michael B Cook
Journal:  Am J Epidemiol       Date:  2016-01-12       Impact factor: 4.897

5.  Androgenetic Alopecia in a Patient with Klinefelter Syndrome: Case Report and Literature Review.

Authors:  Waleed Alsalhi; Antonella Tosti
Journal:  Skin Appendage Disord       Date:  2020-12-07

6.  2D:4D ratio in children at familial high-risk for eating disorders: The role of prenatal testosterone exposure.

Authors:  Radha Kothari; Joseph Gafton; Janet Treasure; Nadia Micali
Journal:  Am J Hum Biol       Date:  2013-12-10       Impact factor: 1.937

Review 7.  Phthalate-Induced Fetal Leydig Cell Dysfunction Mediates Male Reproductive Tract Anomalies.

Authors:  Yiyan Wang; Chaobo Ni; Xiaoheng Li; Zhenkun Lin; Qiqi Zhu; Linxi Li; Ren-Shan Ge
Journal:  Front Pharmacol       Date:  2019-11-06       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.